A T Coste
Overview
Explore the profile of A T Coste including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
178
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Comparison of Three β-Glucan Tests for the Diagnosis of Invasive Candidiasis in Intensive Care Units
Kritikos A, Caruana G, Poissy J, Mamin A, Bachmann D, Pagani J, et al.
J Clin Microbiol
. 2023 Jan;
61(2):e0169122.
PMID: 36700626
The (1→3)-β-d-glucan (BDG) is a marker of invasive fungal infection that can be detected in serum by different commercial kits. In this study, we compared the performance of the Fungitell...
2.
Stavropoulou E, Coste A, Beigelman-Aubry C, Letovanec I, Spertini O, Lovis A, et al.
BMC Infect Dis
. 2020 Jul;
20(1):527.
PMID: 32698804
Background: Conidiobolus spp. (mainly C. coronatus) are the causal agents of rhino-facial conidiobolomycosis, a limited soft tissue infection, which is essentially observed in immunocompetent individuals from tropical areas. Rare cases...
3.
Coste A, Kritikos A, Li J, Khanna N, Goldenberger D, Garzoni C, et al.
Infection
. 2020 Jul;
48(5):761-766.
PMID: 32661647
Echinocandins represent the first-line therapy of candidemia. Echinocandin resistance among Candida spp. is mainly due to acquired FKS mutations. In this study, we report the emergence of FKS-mutant Candida albicans/glabrata...
4.
Caruana G, Croxatto A, Coste A, Opota O, Lamoth F, Jaton K, et al.
Clin Microbiol Infect
. 2020 Jun;
26(9):1178-1182.
PMID: 32593741
Background: To face the current COVID-19 pandemic, diagnostic tools are essential. It is recommended to use real-time RT-PCR for RNA viruses in order (a) to perform a rapid and accurate...
5.
Croxatto A, Coste A, Pillonel T, Bertelli C, Greub G, Prodhom G
Clin Microbiol Infect
. 2019 Oct;
26(5):644.e9-644.e15.
PMID: 31634549
Objectives: Becton-Dickinson recently developed the Phoenix™ CPO (carbapenemase-producing organism) Detect Test, a growth-based test embedded in Gram-negative (GN) panels for the detection and confirmation of bacteria producing class A, B...
6.
Coste A, Imbert C, Hennequin C
J Mycol Med
. 2019 Jun;
29(2):105-106.
PMID: 31178041
No abstract available.
7.
Glampedakis E, Coste A, Aruanno M, Bachmann D, Delarze E, Erard V, et al.
Antimicrob Agents Chemother
. 2018 Oct;
62(12).
PMID: 30323034
Invasive fungal infections due to with decreased azole susceptibility are emerging in the setting of azole prophylaxis and are associated with poor outcomes. We assessed the activity of antifungal drugs...
8.
Vale-Silva L, Coste A, Ischer F, Parker J, Kelly S, Pinto E, et al.
Antimicrob Agents Chemother
. 2012 Jan;
56(4):1960-8.
PMID: 22252807
The inactivation of ERG3, a gene encoding sterol Δ⁵,⁶-desaturase (essential for ergosterol biosynthesis), is a known mechanism of in vitro resistance to azole antifungal drugs in the human pathogen Candida...